Eli Lilly & Co on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the treatment in hospitalized COVID-19 patients was paused due to safety concerns.
Lilly said on Tuesday that an independent safety monitoring board requested a pause in the trial, called ACTIV-3, due to a potential safety issue.
Lilly on Wednesday said the paused trial is distinct from others it is conducting because it focuses on hospitalized patients who are more severely ill and being treated with other drugs as well, including Gilead Sciences Inc’s antiviral remdesivir. Trump touted both drugs as being tantamount to cures in a video he posted last week after being released from the hospital.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly pauses trial of its monoclonal antibody to treat Covid-19 for safety reasonsThe coronavirus pandemic has brought countries to a standstill. In many places, as countries reopen, Covid-19 cases are on the rise. Follow here for the latest.
Read more »
Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To 'Potential Safety Concern'President Trump has promoted the company’s antibody treatment in recent videos.
Read more »
Report: Eli Lilly In Violation Of FDA Manufacturing Standards At Plant Preparing To Produce Covid TreatmentOn October 7, Lilly announced it had applied for an emergency use authorization for its treatment from the FDA.
Read more »
Exclusive: FDA faults quality control at Lilly plant making Trump-touted COVID drugU.S. drug inspectors uncovered serious quality control problems at an Eli Lilly and Co pharmaceutical plant that is ramping up to manufacture one of two promising COVID-19 drugs touted by President Trump as 'a cure' for the disease, according to government documents and...
Read more »
Eli Lilly antibody trial paused due to potential safety concern"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety
Read more »
Eli Lilly antibody trial paused due to potential safety concernU.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.
Read more »